The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity

Ferroptosis offers a route to hepatocellular carcinoma (HCC) vulnerability whose immunological consequences depend on the affected cell and its death or stress state. This structured evidence-mapped critical review integrates mechanistic causality, model context, traditional Chinese medicine (TCM) provenance, and cellular attribution across tumor, immune, and hepatic compartments. Seven full-text-verified Broad-TCM HCC studies comprised two M1 and five M2 studies: one-sided evidence and same-system ferroptosis-related and immune effects, respectively. This distribution identifies matched causal mediation as the next experimental priority. Direct-HCC and non-HCC mechanistic studies explain how tumor-cell ferroptosis can engage antitumor immunity while lipid-peroxidative injury to effector lymphocytes, dendritic cells, or nonmalignant hepatocytes can impair treatment. We propose a cell-selective immunoferroptosis framework that couples tumor-cell ferroptotic death to preservation of beneficial immune function and nonmalignant liver, with suppressive myeloid populations targeted according to their functional response. Development proceeds from cell-resolved causal rescue and immune-dependency testing to comparative assessment of tumor, immune, and hepatic effects at effective exposures. Clinical studies then connect deliverable exposure, biomarker concordance, efficacy, and hepatic safety within defined treatment and etiological settings. This evidence-based sequence provides a pharmacological research agenda for translating TCM-related ferroptosis–immune observations into testable therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.2006020
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity

Xinrui Li, Chongyu Wang, Yu Li, Xiaojie Ji
3 links
Frontiers in Pharmacology
Ferroptosis and cancer prognosis
article

The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity

Xinrui Li, Chongyu Wang, Yu Li, Xiaojie Ji
article en

Abstract

Ferroptosis offers a route to hepatocellular carcinoma (HCC) vulnerability whose immunological consequences depend on the affected cell and its death or stress state. This structured evidence-mapped critical review integrates mechanistic causality, model context, traditional Chinese medicine (TCM) provenance, and cellular attribution across tumor, immune, and hepatic compartments. Seven full-text-verified Broad-TCM HCC studies comprised two M1 and five M2 studies: one-sided evidence and same-system ferroptosis-related and immune effects, respectively. This distribution identifies matched causal mediation as the next experimental priority. Direct-HCC and non-HCC mechanistic studies explain how tumor-cell ferroptosis can engage antitumor immunity while lipid-peroxidative injury to effector lymphocytes, dendritic cells, or nonmalignant hepatocytes can impair treatment. We propose a cell-selective immunoferroptosis framework that couples tumor-cell ferroptotic death to preservation of beneficial immune function and nonmalignant liver, with suppressive myeloid populations targeted according to their functional response. Development proceeds from cell-resolved causal rescue and immune-dependency testing to comparative assessment of tumor, immune, and hepatic effects at effective exposures. Clinical studies then connect deliverable exposure, biomarker concordance, efficacy, and hepatic safety within defined treatment and etiological settings. This evidence-based sequence provides a pharmacological research agenda for translating TCM-related ferroptosis–immune observations into testable therapeutic strategies.

Frontiers in PharmacologyVol. 17
First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN)
Good health and well-being
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon